Predicting neutralization susceptibility to combination HIV-1 monoclonal broadly neutralizing antibody regimens.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 13 05 2024
accepted: 21 08 2024
medline: 6 9 2024
pubmed: 6 9 2024
entrez: 6 9 2024
Statut: epublish

Résumé

Combination monoclonal broadly neutralizing antibodies (bnAbs) are currently being developed for preventing HIV-1 acquisition. Recent work has focused on predicting in vitro neutralization potency of both individual bnAbs and combination regimens against HIV-1 pseudoviruses using Env sequence features. To predict in vitro combination regimen neutralization potency against a given HIV-1 pseudovirus, previous approaches have applied mathematical models to combine individual-bnAb neutralization and have predicted this combined neutralization value; we call this the combine-then-predict (CP) approach. However, prediction performance for some individual bnAbs has exceeded that for the combination, leading to another possibility: combining the individual-bnAb predicted values and using these to predict combination regimen neutralization; we call this the predict-then-combine (PC) approach. We explore both approaches in both simulated data and data from the Los Alamos National Laboratory's Compile, Neutralize, and Tally NAb Panels repository. The CP approach is superior to the PC approach when the neutralization outcome of interest is binary (e.g., neutralization susceptibility, defined as inhibitory 80% concentration < 1 μg/mL). For continuous outcomes, the CP approach performs nearly as well as the PC approach when the individual-bnAb prediction algorithms have strong performance, and is superior to the PC approach when the individual-bnAb prediction algorithms have poor performance. This knowledge may be used when building prediction models for novel antibody combinations in the absence of in vitro neutralization data for the antibody combination; this, in turn, will aid in the evaluation and down-selection of these antibody combinations into prevention efficacy trials.

Identifiants

pubmed: 39240995
doi: 10.1371/journal.pone.0310042
pii: PONE-D-24-19268
doi:

Substances chimiques

Antibodies, Neutralizing 0
HIV Antibodies 0
Antibodies, Monoclonal 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0310042

Informations de copyright

Copyright: © 2024 Williamson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Brian D Williamson (BD)

Biostatistics Division, Kaiser Permanente Washington Health Research Institute, Seattle, WA, United States of Amerrica.
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States of Amerrica.
Department of Biostatistics, University of Washington, Seattle, WA, United States of Amerrica.

Liana Wu (L)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States of Amerrica.

Yunda Huang (Y)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States of Amerrica.
Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, United States of Amerrica.
Department of Global Health, University of Washington, Seattle, WA, United States of Amerrica.

Aaron Hudson (A)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States of Amerrica.
Department of Biostatistics, University of Washington, Seattle, WA, United States of Amerrica.
Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, United States of Amerrica.

Peter B Gilbert (PB)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States of Amerrica.
Department of Biostatistics, University of Washington, Seattle, WA, United States of Amerrica.
Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, United States of Amerrica.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH